Fig. 3: Outcome from HSCT according to MDS subtype and karyotype.

A Disease-free survival according to most advanced MDS type prior to transplantation, B Disease-free survival, and C cumulative incidence of relapse according to most advanced MDS type stratified by karyotype. RCC refractory cytopenia of childhood, MDS-EB MDS with excess blasts, MDS-EBt MDS with excess blasts in transformation, AML MDS-related acute myeloid leukemia, N numbers in subgroup, E events.